Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid Tumors

NCT06337630 is registered in ClinicalTrials.gov with Institut Curie as lead sponsor.

NCT NCT06337630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06337630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid Tumors
Lead sponsor
Institut Curie
Phase
Phase 1
Overall status
Terminated
Start date
January 20, 2025
Completion date
November 24, 2025
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor